Lotus Pharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	6,195	7,740	6,030	1,771	1,983	1,605
Cash & Short-Term Investments	6,195	7,740	6,030	1,771	1,983	1,605
Cash Growth	10.53%	28.35%	240.51%	-10.71%	23.54%	7.82%
Accounts Receivable	8,290	6,863	7,435	6,384	4,651	3,266
Other Receivables	877.05	936.56	268.54	233.13	276.24	141.56
Receivables	9,167	7,799	7,703	6,617	4,927	3,407
Inventory	9,252	9,649	3,833	3,775	3,330	3,073
Other Current Assets	1,282	1,264	531.5	489.37	420.4	247.24
Total Current Assets	25,896	26,453	18,098	12,653	10,661	8,333
Property, Plant & Equipment	7,679	7,607	3,666	3,511	3,148	2,642
Long-Term Investments	580	463.88	3,594	3,048	2,158	301.73
Goodwill	-	31,955	6,127	5,670	5,668	5,586
Other Intangible Assets	58,727	12,204	5,199	5,487	5,910	2,971
Long-Term Accounts Receivable	-	113.85	122.73	152.6	-	-
Long-Term Deferred Tax Assets	14,098	13,942	486.42	411.69	390.12	310.82
Long-Term Deferred Charges	-	13,119	2,639	1,878	1,406	891.98
Other Long-Term Assets	554.56	295.86	168.74	180.28	185.33	185.35
Total Assets	107,534	106,154	40,101	32,992	29,526	21,222
Accounts Payable	3,028	2,416	1,070	670.8	1,403	747.55
Accrued Expenses	-	2,850	-	3.06	3.57	0.93
Short-Term Debt	1,567	1,609	1,615	510	155.92	1,377
Current Portion of Long-Term Debt	1,803	2,541	3,390	1,303	59.95	794.9
Current Portion of Leases	170.24	159.63	84.32	70.24	58.99	62.47
Current Income Taxes Payable	1,448	1,416	664.47	436.56	731.15	280.16
Current Unearned Revenue	151.3	179.16	180.9	132.85	183.08	132.01
Other Current Liabilities	8,072	5,707	1,433	1,398	3,297	931.26
Total Current Liabilities	16,238	16,879	8,438	4,524	5,893	4,326
Long-Term Debt	43,708	42,447	8,384	9,519	8,596	4,667
Long-Term Leases	755.15	718.62	194.06	182.2	46.82	43.41
Long-Term Unearned Revenue	13.99	16.29	26.56	45.33	65.92	85.96
Pension & Post-Retirement Benefits	-	767.52	673.52	503.28	371.91	502.7
Long-Term Deferred Tax Liabilities	1,767	1,697	1,093	721.2	448.4	304.15
Other Long-Term Liabilities	21,019	19,848	112.17	162.29	235.84	224.03
Total Liabilities	83,501	82,374	18,921	15,658	15,658	10,153
Common Stock	2,669	2,669	2,659	2,650	2,626	2,628
Additional Paid-In Capital	7,642	7,642	7,431	7,131	7,534	8,039
Retained Earnings	15,797	15,904	12,660	8,900	4,823	1,701
Treasury Stock	-824.16	-824.16	-48.39	-51.1	-57.35	-57.75
Comprehensive Income & Other	-1,251	-1,610	-1,521	-1,295	-1,058	-1,241
Total Common Equity	24,032	23,780	21,180	17,334	13,868	11,069
Shareholders' Equity	24,032	23,780	21,180	17,334	13,868	11,069
Total Liabilities & Equity	107,534	106,154	40,101	32,992	29,526	21,222
Total Debt	48,003	47,476	13,667	11,585	8,918	6,944
Net Cash (Debt)	-41,807	-39,736	-7,636	-9,814	-6,935	-5,339
Net Cash Per Share	-160.32	-151.87	-28.99	-37.45	-26.50	-20.80
Filing Date Shares Outstanding	283.6	262.81	265.39	264.47	262.04	262.25
Total Common Shares Outstanding	283.6	262.81	265.39	264.47	262.04	262.25
Working Capital	9,658	9,574	9,660	8,129	4,768	4,007
Book Value Per Share	84.74	90.48	79.81	65.54	52.92	42.21
Tangible Book Value	-34,695	-20,380	9,855	6,177	2,291	2,512
Tangible Book Value Per Share	-122.34	-77.54	37.13	23.36	8.74	9.58
Land	-	624.65	599.33	622.55	622.31	615.49
Buildings	-	4,031	2,074	1,888	1,384	1,313
Machinery	-	3,622	1,865	1,826	1,547	1,408
Construction In Progress	-	657.97	706.38	639.41	1,077	675.22
Leasehold Improvements	-	127.33	100.15	71.01	87.87	78.26